Table 2:

Primary and secondary outcomes

	Intervention group (n=195)	Standard-of-care group (n=195)	Absolute risk difference, % (95% CI)	p value
Composite primary outcome	175 (90%)	148 (76%)	13·9% (6·4 to 21·2)	0·00040
Components of primary outcome
Viral suppression (<200 copies per mL)	182 (93%)	162 (83%)	10·3% (3·9 to 16·8)	0·0025
Retention in care at study clinic	180 (92%)	165 (85%)	7·7% (1·3 to 14·2)	0·026
Other secondary outcomes
Viral suppression (<200 copies per mL) and retention at any clinic	177 (91%)	153 (79%)	12·3% (5·2 to 19·4)	0·0011
Viral load <1000 copies per mL and retention at study clinic	176 (90%)	152 (78%)	12·3% (5·1 to 19·5)	0·0013
Viral load <50 copies per mL and retention at study clinic	167 (86%)	139 (71%)	14·4% (6·2 to 22·3)	0·0080
Viral load <1000 copies per mL	184 (94%)	166 (85%)	9·2% (3·2 to 15·4)	0·0041
Viral load <50 copies per mL	172 (88%)	152 (78%)	10·3% (2·8 to 17·6)	0·0099
Retention in care at any clinic at 12 months	182 (93%)	170 (87%)	6·2% (0·2 to 12·2)	0·059
Viral suppression among those with a result at study exit
Viral load <1000 copies per ml	184/189 (97%)	166/178 (93%)	4·1% (–0·3 to 9·0)	0·082
Viral load <200 copies per ml	182/189 (96%)	162/178 (91%)	5·3% (0·2 to 10·7)	0·051
Viral load <50 copies per ml	172/189 (91%)	152/178 (85%)	5·6% (–1·0 to 12·4)	0·11
Communication of viral load result to participant
Enrolment viral load communicated to participant	195/195 (100%)	171/192 (89%)	10·9% (6·8 to 16·1)	<0·0001
Mid-study viral load communicated to participant	191/192 (>99%)	127/170 (75%)	24·8% (18·4 to 31·8)	<0·0001
All viral load results communicated to participant	397/398 (>99%)	304/373 (82%)	18·3% (14·5 to 22·5)	<0·0001
Referral into community-based ART delivery programme	116 (60%)	52 (27%)	32·8% (23·2 to 41·6)	<0·0001

Data are n (%) or n/N (%), unless otherwise stated. ART=antiretroviral therapy.